Form 4 for AKTX Akari Therapeutics Plc
Accepted 2024-05-03 00:00:00 ET · period of report 2024-05-01 · accession 0000950170-24-053000 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-05-03 | 2024-05-01 | AKTX | DICICCO WENDY F | Interim CFO | A - Grant | $0.00 | +158.47M | 158.47M | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Ordinary Shares, par value $0.0001 per share | 2024-05-01 | A | A | 158,473,915 | $0.00 | 158,473,915 | D | — | — | (F1) These shares represent restricted stock units ("RSUs") granted under the Issuer's 2023 Equity Incentive Plan, with each such RSU representing the right to receive one ordinary share, par value $0.0001. One-hundered percent (100%) of the RSUs shall vest on May 1, 2025 (first anniversary of the date of grant), subject to the Reporting Person's continued service with the Issuer on the vesting date. Notwithstanding the foregoing, should the Issuer terminate the Reporting Person for any reason other than for cause prior to the vesting date, the RSUs will continue to vest through the first anniversary of the date of grant or be accelerated, at the Issuer's option. |